HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

Haematologica

Volumn 98, Issue 8, 2013, Pages 1216-1225

  Dickson, Glenda J ^a   Liberante, Fabio G ^a   Kettyle, Laura M ^a   O'Hagan, Kathleen A ^a   Finnegan, Damian P J ^a   Bullinger, Lars ^b   Geerts, Dirk ^c   McMullin, Mary Frances ^a   Lappin, Terry R J ^a   Mills, Ken I ^a   Thompson, Alexander ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULM   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CYTARABINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR PBX3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOTHERAPY; COLONY FORMING UNIT; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CYTOGENETIC ANALYSIS; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; U937 CELLS;

EID: 84881020961     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.079012     Document Type: Article

References (43)

1. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86.
2. Grimwade D, Mrozek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am. 2011;25(6):1135-61, vii.
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.
4. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605-16.
5. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-95.
6. Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or highrisk myelodysplastic syndrome following induction chemotherapy. Leuk Res. 2009;33(9):1189-93.
7. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385-400.
8. Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118(4):1069-76.
9. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-6.
10. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-9.
11. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747-54.
12. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-33.
13. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 2002;16(2):186-95.
14. Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, Grimes S, et al. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by smallarray real-time PCR. Blood. 2003;101(4): 1558-65.
15. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, Rohatiner A, et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocationmediated fusion events. Genes Chromosomes Cancer. 2003;37(2):149-58.
16. Lebert-Ghali CE, Fournier M, Dickson GJ, Thompson A, Sauvageau G, Bijl JJ. HoxA cluster is haploinsufficient for activity of hematopoietic stem and progenitor cells. Exp Hematol. 2010;38(11):1074-86 e1-5.
17. Dickson GJ, Kwasniewska A, Mills KI, Lappin TR, Thompson A. Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal. Exp Hematol. 2009;37(3):322-33 e3.
18. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, et al. Overexpression of the myeloid leukemiaassociated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002;99(1):121-9.
19. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood. 2010;115(14):2910-8.
20. Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood. 1997;89(6):1922-30.
21. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21(1):224-34.
22. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17(13):3714-25.
23. Nakamura T, Jenkins NA, Copeland NG. Identification of a new family of Pbx-related homeobox genes. Oncogene. 1996;13(10):2235-42.
24. Monica K, Galili N, Nourse J, Saltman D, Cleary ML. PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol Cell Biol. 1991;11(12):6149-57.
25. Selleri L, DiMartino J, van Deursen J, Brendolan A, Sanyal M, Boon E, et al. The TALE homeodomain protein Pbx2 is not essential for development and long-term survival. Mol Cell Biol. 2004;24(12):5324-31.
26. Rhee JW, Arata A, Selleri L, Jacobs Y, Arata S, Onimaru H, et al. Pbx3 deficiency results in central hypoventilation. Am J Pathol. 2004;165(4):1343-50.
27. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15):2529-37.
28. Klein HU, Ruckert C, Kohlmann A, Bullinger L, Thiede C, Haferlach T, et al. Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. BMC Bioinformatics. 2009;10: 422.
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
30. Ferrari F, Bortoluzzi S, Coppe A, Sirota A, Safran M, Shmoish M, et al. Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics. 2007;8: 446.
31. Dickson GJ, Lappin TR, Thompson A. Complete array of HOX gene expression by RQ-PCR. Methods Mol Biol. 2009;538:369-93.
32. Drexler HG, MacLeod RAF, Nagel S, Dirks WG, Uphoff CC, Steube KG, et al. Guide to leukemia-lymphoma cell lines on CD. Blood. 2005;106(11):165.
33. Tiacci E, Spanhol-Rosseto A, Martelli MP, Pasqualucci L, Quentmeier H, Grossmann V, et al. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. Leukemia. 2012;26(3):554-7.
34. Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, et al. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004;12(5):1115-20.
35. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101(11):4589-97.
36. Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HJ, Largman C. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol. 1999;19(4):3051-61.
37. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
38. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963-72.
39. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and ratelimiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21(21):2762-74.
40. De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10): 1548-51.
41. Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47(5):827-36.
42. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, et al. Up-regulation of a HOXAPBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119(10):2314-24.
43. Li Z, Huang H, Li Y, Arnovitz S, Chen P, Huang H, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121(8):1422-31.